Literature DB >> 22499012

Case report: risk of virus infection after accidental blood inoculation from a multi-infected AIDS patient.

Annemarie Berger1, M Stürmer, H W Doerr.   

Abstract

Infections caused by blood-borne viruses such as hepatitis B and C and the human immunodeficiency virus (HIV) are associated commonly with needlestick injuries, especially in a hospital setting. A prospective investigation was conducted on a medical doctor who suffered an accidental needlestick injury during blood collection from a patient with AIDS. The patient's blood contained 195,000 copies of HIV RNA, 1 × 10(6) IU hepatitis C virus (HCV) RNA, and >10(7) copies of parvovirus B19 DNA per 1 ml plasma. It was positive for cytomegalovirus virus and evidence of a resolved hepatitis B virus (HBV) infection was found. HCV viremia was detected in the physician 15 days later and was not resolved by seroconversion after 57 days. HIV infection was not transmitted, possibly because of the immediate use of anti-HIV prophylactic drugs after exposure. Parvovirus B19 infection was presumably prevented by pre-existing specific antibodies in the patient. Considering that many HIV carriers are coinfected with hepatitis B and C viruses, this case report support the knowledge that the risk of HCV transmission from a patient with AIDS is greater than that of HIV.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22499012     DOI: 10.1002/jmv.23286

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  2 in total

1.  The management of needlestick injuries.

Authors:  Heiko Himmelreich; Holger F Rabenau; Matthias Rindermann; Christoph Stephan; Markus Bickel; Ingo Marzi; Sabine Wicker
Journal:  Dtsch Arztebl Int       Date:  2013-02-01       Impact factor: 5.594

2.  [Early diagnosis of hepatitis C transmission after needlestick injury].

Authors:  H Himmelreich; C M Sarrazin; C Stephan; H F Rabenau; I Marzi; S Wicker
Journal:  Unfallchirurg       Date:  2013-07       Impact factor: 1.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.